We are live on ! Find out more
RCM

RA Capital Management Portfolio holdings

AUM $9.44B
1-Year Est. Return 157.3%
This Fund
S&P 500
This Quarter Est. Return
-13.03%
1 Year Est. Return
+157.3%
3 Year Est. Return
+589.39%
5 Year Est. Return
+654.96%
10 Year Est. Return
+50,915.53%
AUM
$696M
AUM Growth
-$298M
Cap. Flow
-$81.5M
Cap. Flow %
-11.71%
Top 10 Hldgs %
54.99%
Holding
76
New
17
Increased
7
Reduced
14
Closed
29

Top Buys

Rank Stock Value
1
ZGNX
Zogenix, Inc.
ZGNX
+$30.3M
2
GBT
Global Blood Therapeutics, Inc.
GBT
+$21.6M
3
AIMT
Aimmune Therapeutics
AIMT
+$18.5M
4
NGNE icon
Neurogene
NGNE
+$17.6M
5
SRRA
Sierra Oncology, Inc. Common Stock
SRRA
+$17.1M

Top Sells

Rank Stock Value
1
MDCO
Medicines Co
MDCO
+$20.2M
2
BCRX icon
BioCryst Pharmaceuticals
BCRX
+$18.8M
3
DVAX
Dynavax Technologies
DVAX
+$17.9M
4
JUNO
Juno Therapeutics, Inc.
JUNO
+$14.9M
5
NVAX icon
Novavax
NVAX
+$14.2M

Sector Composition

Rank Sector Weight
1 Healthcare 85.07%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
XNCR icon
26
Xencor
XNCR
$1.45B
$8.31M 1.19%
679,885
-395,525
-37% -$7.74M
SGMO
27
DELISTED
SANGAMO THERAPEUTICS INC
SGMO
$8.15M 1.17%
1,445,430
+225,221
+18% +$1.86M
TENX icon
28
Tenax Therapeutics
TENX
$393M
$8.01M 1.15%
83
– –
ALPN
29
DELISTED
Alpine Immune Sciences Inc
ALPN
$7.95M 1.14%
153,216
-36,100
-19% -$2.37M
ZYNE
30
DELISTED
Zynerba Pharmaceuticals, Inc
ZYNE
$7.51M 1.08%
+525,000
New +$12.9M
MCRB icon
31
Seres Therapeutics
MCRB
$45M
$7.31M 1.05%
12,332
– –
AKTX
32
Akari Therapeutics
AKTX
$14.4M
$6.33M 0.91%
+330
New +$3.9M
RARE icon
33
Ultragenyx Pharmaceutical
RARE
$2.46B
$5.4M 0.78%
+56,067
New +$6.42M
ALNY icon
34
Alnylam Pharmaceuticals
ALNY
$38.3B
$5.07M 0.73%
+63,026
New +$7M
BLCM
35
DELISTED
Bellicum Pharmaceuticals, Inc.
BLCM
$4.59M 0.66%
31,570
-71,070
-69% -$13M
AGRX
36
DELISTED
Agile Therapeutics
AGRX
$4.25M 0.61%
315
-414
-57% -$7.35M
ORKA
37
Oruka Therapeutics
ORKA
$5.31B
$4.02M 0.58%
3,756
– –
VTAE
38
DELISTED
VITAE PHARMACEUTICALS INC COMMON STOCK
VTAE
$3.54M 0.51%
+321,161
New +$3.41M
EPZM
39
DELISTED
Epizyme, Inc
EPZM
$2.92M 0.42%
+227,092
New +$4.58M
CYTO
40
DELISTED
Altamira Therapeutics Ltd
CYTO
$1.67M 0.24%
6
-6
-50% -$2.3M
AGTC
41
DELISTED
Applied Genetic Technologies Corporation
AGTC
$1.59M 0.23%
+121,100
New +$2.01M
NVAX icon
42
Novavax
NVAX
$1.21B
$1.15M 0.16%
8,103
-63,459
-89% -$14.2M
FRTX
43
DELISTED
Fresh Tracks Therapeutics, Inc. Common Stock
FRTX
$958K 0.14%
662
-166
-20% -$320K
BNTC icon
44
Benitec Biopharma
BNTC
$414M
$864K 0.12%
+551
New +$1.03M
DRRX
45
DELISTED
DURECT Corp
DRRX
$745K 0.11%
38,180
– –
WGBS
46
DELISTED
WaferGen Bio-systems, Inc.
WGBS
$279K 0.04%
41,080
– –
ARMP icon
47
Armata Pharmaceuticals
ARMP
$168M
$257K 0.04%
+465
New +$425K
ACAD icon
48
Acadia Pharmaceuticals
ACAD
$4.51B
– –
-27,300
Closed -$1.14M
AGEN
49
Agenus
AGEN
$276M
– –
-81,520
Closed -$13.8M
AGIO icon
50
Agios Pharmaceuticals
AGIO
$2.08B
– –
-9,900
Closed -$1.1M
1
2
3 4

Similar funds

RCMNY
Rubric Capital Management (New York) New York $9.44B AUM 68.42% 1-Year Est. Return
SCM
SCS Capital Management Boston, Massachusetts $9.44B AUM 18.1% 1-Year Est. Return
SIM
SRS Investment Management New York $9.47B AUM 60.12% 1-Year Est. Return
NPT
National Philanthropic Trust Jenkintown, Pennsylvania $9.38B AUM 33.37% 1-Year Est. Return
AC
Allstate Corporation Northbrook, Illinois $9.35B AUM 16.13% 1-Year Est. Return
PVI
Partners Value Investments Hamilton, Bermuda $9.34B AUM 12.2% 1-Year Est. Return
WPL
WINDACRE PARTNERSHIP LLC Houston, Texas $9.34B AUM 17.41% 1-Year Est. Return
BAMF
BI Asset Management Fondsmaeglerselskab Kobenhavn, Denmark $9.55B AUM 31.94% 1-Year Est. Return

RA Capital Management's Q3 2015 Portfolio in Review

As of Q3 2015, RA Capital Management held 76 positions worth $696M, down 30% from $994M the previous quarter. Its ten largest holdings account for 55% of the portfolio.

RA Capital Management withdrew a net $81.5M in Q3 2015, closing 29 positions and reducing 14 holdings. Its most notable exit was Medicines Co, an estimated $20.2M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 85% of assets, up from 76% a quarter earlier.

Against the trend, RA Capital Management opened a new position in Zogenix, Inc. worth $22.7M.

  • RA Capital Management's largest Q3 2015 buy was Zogenix, Inc.: 1,679,500 shares worth $22.7M.
  • RA Capital Management added most to Achillion Pharmaceuticals in Q3 2015, an estimated $14.6M increase.
  • RA Capital Management's biggest Q3 2015 reduction was BioCryst Pharmaceuticals, cutting an estimated $18.8M.
  • RA Capital Management fully exited Medicines Co in Q3 2015, selling an estimated $20.2M.
  • RA Capital Management's ten largest holdings make up 55% of its $696M portfolio in Q3 2015.
  • RA Capital Management opened 17 new positions and closed 29 in Q3 2015.
  • RA Capital Management's portfolio value fell 30% quarter-over-quarter to $696M.

Based on RA Capital Management's 13F filing for Q3 2015, filed 13 Nov 2015.